knowledge -WSS

knowledge

author：knowledge 2025-09-30 20:06:52 - browse：6581

Amylyx founders — Justin Klee (left) and Joshua Cohen are the co-founders and co-CEOs of Amylyx Pharmaceuticals. Kayana Szymczak for STAT

Amylyx Pharmaceuticals said Friday that its treatment for ALS, called Relyvrio, failed to provide any benefit for patients in a large clinical trial — a stunning outcome that now has the company considering a voluntary withdrawal of the approved medicine from the market.

“This is really hard for us, and it’s really hard for our team who care so much, but it’s so much harder for people with ALS and their families, and we have to keep that perspective,” said a somber Justin Klee, Amylyx’s co-founder and co-CEO, in an interview with STAT on Thursday evening.

In the Phase 3 study involving 664 people with ALS, Relyvrio failed to outperform a placebo on an ALS functional rating scale that measures the ability to perform daily living tasks, walk, breathe, speak, and swallow. The company did not provide detailed results for the study’s primary goal, but said the calculation for statistical significance was 0.67 — well above the 0.05 threshold for success and an indication that Relyvrio provided no benefit at all.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： Buoyed by wins on obesity, Novo Nordisk eyes heart disease

focus

leisure time

WSS

Bryan Kohberger seeks indictment dismissal in Idaho college killings case

Hospitals look to new technology to keep health care workers safe

Biden to sign 'historic' executive order on how US military handles sexual assault cases

NYU radiologists take on the challenge of expensive MRI machines

FDA's Woodcock to retire early next year

Stoke drug shows lower activity against childhood epilepsy

hotspot

knowledge

hotspot

Malaria cases in Florida and Texas: Here’s what you need to know

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

Apple is now the first public company to be valued at $3 trillion

Ending health disparities requires full federal government, panel says

Medical leaders decry Supreme Court decision on affirmative action

Why medical students are struggling with mental health

Sports medicine is finally prioritizing gender equality

Weight loss drug costs may need more research, senator suggests

Guidelines to prevent youth baseball injuries need more muscle

Childhood cancer progress stalls for Black, Hispanic kids: Report

knowledge

Bryan Kohberger seeks indictment dismissal in Idaho college killings case

Public health communication lessons from Covid

Hospitals look to new technology to keep health care workers safe

A daunting task: navigating dual Medicare, Medicaid eligibility

VC firm RA Capital starts a new synthetic biology incubator

World's first CRISPR

focus

entertainment

leisure time

knowledge